Asset
PICLIDENOSON
CAN-FITE BIOPHARMA LTD AMERICAN DEPOSITARY SHARES EACH REPRESENTING TWO (2) ORDINARY SHARES
Revenue
No revenue reported in loaded filings.
Clinical trials (15)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06643260 | phase3 | not_yet_recruiting | 2025-06-01 | 2027-12-01 | Can-Fite BioPharma | A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy |
| NCT00837291 | phase2 | withdrawn | 2018-11-01 | 2018-12-01 | Can-Fite BioPharma | A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the Knee |
| NCT07410455 | phase2 | not_yet_recruiting | 2026-06-01 | 2027-08-31 | Can-Fite BioPharma | An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe Syndrome |
| NCT02647762 | phase3 | terminated | 2017-10-30 | 2020-11-30 | Can-Fite BioPharma | CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis |
| NCT03168256 | phase3 | completed | 2018-09-15 | 2022-01-06 | Can-Fite BioPharma | CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis |
FDA applications (0)
This company has no applications containing this asset.